Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (14567)	2/11/1998 2:17:00 AM
From: John Zwiener	Respond to of 32384

Never mind, Bernie has answered that question as to if one of these drugs may work in a carcinoma (breast). Not bad. Two messages posted while I wrote up that last message. Late night people.

To: Flagrante Delictu who wrote (14567)	2/11/1998 2:33:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Bernie, Speaking of breast cancer, there are really several avenues that are being actively pursued by LGND. The government has at least two studies started that use Panretin in combination therapy with Tamoxifen, the current hormone treatment of choice for Breast cancer. Tamoxifen is a SERM and, as you know, LGND is involved with 4 SERMs in addition to the combination trials with Tamoxifen. PFE is developing Droloxifene and CP-366,156 for osteoporosis although they indicated that they would be looking at the use of Droloxifene to prevent breast cancer. This quarter, AHP is slated to enter their first SERM, TSE424, into the clinic, also for osteoporosis. LGND's alliance with LLY specifically targets cancer treatment (and I think that you can safely assume that breast cancer is at the top of the target list) with a combination of a rexinoid (Targretin or one of the two second generation rexinoids) with a SERM (Evista, aka Raloxifene). Moreover, LGND has already used animal models to show that Targretin can prevent breast cancer and can overcome the undesired side effect of uterine growth caused by Tamoxifen (and the Tamoxifen prevention trial was terminated because of to much proliferation of endometrial tissues in women in the prevention trial). Thus LGND is well poised to attack and prevent breast cancer on several fronts. Moreover, the recent report on use of Vitamin D derivatives to treat breast cancer is also of interest, because the Vitamin D receptor forms a heteroduplex with RXRs and the vitamin D derivative and Panretin produce additive effects when used to treat breast cancer cells in vitro.